| Dr Michael Angelo Pezzone, MD | |
|
1515 Locust St Ste 500, Pittsburgh, PA 15219-5131 | |
| (412) 232-8888 | |
| (412) 232-8887 |
| Full Name | Dr Michael Angelo Pezzone |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 30 Years |
| Location | 1515 Locust St Ste 500, Pittsburgh, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164497699 | NPI | - | NPPES |
| ME128692 | Other | FL | STATE LICENSE |
| 001812538 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | ME128692 (Florida) | Secondary |
| 174400000X | Specialist | MD060508L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Upmc Mercy | Pittsburgh, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Pittsburgh Physicians | 8729990239 | 3721 |
News Archive
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
In the event of a free trade agreement with the EU, the UK will continue to be bound by current EU laws, thereby adhering to the new Medical Device Regulation. This will significantly change the landscape of the medical device industry, says GlobalData, a leading data and analytics company.
An international collaboration led by veterinary scientists at Tokyo University of Agriculture and Technology, Japan, has found that size of a dog heart affects both vortex flow and pressure difference in the heart, which both are promising as an index of diastolic function.
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource(R), a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched.
› Verified 4 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
In the event of a free trade agreement with the EU, the UK will continue to be bound by current EU laws, thereby adhering to the new Medical Device Regulation. This will significantly change the landscape of the medical device industry, says GlobalData, a leading data and analytics company.
An international collaboration led by veterinary scientists at Tokyo University of Agriculture and Technology, Japan, has found that size of a dog heart affects both vortex flow and pressure difference in the heart, which both are promising as an index of diastolic function.
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource(R), a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Angelo Pezzone, MD 1515 Locust St Ste 500, Pittsburgh, PA 15219-5131 Ph: (412) 232-8888 | Dr Michael Angelo Pezzone, MD 1515 Locust St Ste 500, Pittsburgh, PA 15219-5131 Ph: (412) 232-8888 |
News Archive
Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington's patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington's often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.
In the event of a free trade agreement with the EU, the UK will continue to be bound by current EU laws, thereby adhering to the new Medical Device Regulation. This will significantly change the landscape of the medical device industry, says GlobalData, a leading data and analytics company.
An international collaboration led by veterinary scientists at Tokyo University of Agriculture and Technology, Japan, has found that size of a dog heart affects both vortex flow and pressure difference in the heart, which both are promising as an index of diastolic function.
Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource(R), a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched.
› Verified 4 days ago